Search

Your search keyword '"Boccomini, C."' showing total 121 results
Start Over Author "Boccomini, C."
121 results on '"Boccomini, C."'

1. Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial

Author

Ladetto, M., Tavarozzi, R., Zanni, M., Evangelista, A., Ferrero, S., Tucci, A., Botto, B., Bolis, S., Volpetti, S., Zilioli, V.R., Puccini, B., Arcari, A., Pavone, V., Gaidano, G., Corradini, P., Tani, M., Cavallo, F., Milone, G., Ghiggi, C., Pinto, A., Pastore, D., Ferreri, A.J.M., Latte, G., Patti, C., Re, F., Benedetti, F., Luminari, S., Pennese, E., Bossi, E., Boccomini, C., Anastasia, A., Bottelli, C., Ciccone, G., and Vitolo, U.

Published
2024
Full Text
View/download PDF

2. Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial

Author

Ladetto, M., primary, Tavarozzi, R., additional, Zanni, M., additional, Evangelista, A., additional, Ferrero, S., additional, Tucci, A., additional, Botto, B., additional, Bolis, S., additional, Volpetti, S., additional, Zilioli, V.R., additional, Puccini, B., additional, Arcari, A., additional, Pavone, V., additional, Gaidano, G., additional, Corradini, P., additional, Tani, M., additional, Cavallo, F., additional, Milone, G., additional, Ghiggi, C., additional, Pinto, A., additional, Pastore, D., additional, Ferreri, A.J.M., additional, Latte, G., additional, Patti, C., additional, Re, F., additional, Benedetti, F., additional, Luminari, S., additional, Pennese, E., additional, Bossi, E., additional, Boccomini, C., additional, Anastasia, A., additional, Bottelli, C., additional, Ciccone, G., additional, and Vitolo, U., additional

Published
2023
Full Text
View/download PDF

3. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)

Author

Luminari, S., Biasoli, I., Versari, A., Rattotti, S., Bottelli, C., Rusconi, C., Merli, F., Spina, M., Ferreri, A.J.M., Zinzani, P.L., Gallamini, A., Franceschetto, A., Boccomini, C., Franceschetti, S., Salvi, F., Raimondo, F.D., Carella, A.M., Micol, Q., Balzarotti, M., Musto, P., and Federico, M.

Published
2014
Full Text
View/download PDF

4. S209: PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUTINIB IN COMBINATION WITH BENDAMUSTINE-RITUXIMAB (BR) AND R MAINTENANCE AS A FIRST-LINE TREATMENT FOR OLDER PATIENTS WITH MANTLE-CELL LYMPHOMA

Author

Wang, M. L., primary, Jurczak, W., additional, Jerkeman, M., additional, Trotman, J., additional, Zinani, P. L., additional, Belada, D., additional, Boccomini, C., additional, Flinn, I. W., additional, Giri, P., additional, Goy, A., additional, Hamlin, P. A., additional, Hermine, O., additional, Hernández-Rivas, J.-Á., additional, Hong, X., additional, Kim, S. J., additional, Lewis, D., additional, Mishima, Y., additional, Özcan, M., additional, Perini, G. F., additional, Pocock, C., additional, Song, Y., additional, Spurgeon, S. E., additional, Storring, J. M., additional, Walewski, J., additional, Zhu, J., additional, Qin, R., additional, Henninger, T., additional, Deshpande, S., additional, Howes, A., additional, Le Gouill, S., additional, and Dreyling, M., additional

Published
2022
Full Text
View/download PDF

5. P1144: RADIOIMMUNOTHERAPY (RIT) VERSUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ASCT) IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA: A FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III TRIAL.

Author

Ladetto, M., primary, Tavarozzi, R., additional, Evangelista, A., additional, Zanni, M., additional, Tucci, A., additional, Anastasia, A., additional, Botto, B., additional, Boccomini, C., additional, Bolis, S., additional, Volpetti, S., additional, Zilioli, V. R., additional, Puccini, B., additional, Arcari, A., additional, Pavone, V., additional, Gaidano, G., additional, Corradini, P., additional, Tani, M., additional, Ferrero, S., additional, Cavallo, F., additional, Milone, G., additional, Ghiggi, C., additional, Pinto, A., additional, Pastore, D., additional, Ferreri, A. J., additional, Latte, G., additional, Patti, C., additional, Re, F., additional, Arcaini, L., additional, Benedetti, F., additional, Usai, S. V., additional, Luminari, S., additional, Mannina, D., additional, Pulsoni, A., additional, Stelitano, C., additional, Pennese, E., additional, Pietrantuono, G., additional, Gherlinzoni, F., additional, Pomponi, F., additional, Olivieri, A., additional, Perrone, T., additional, Rota Scalabrini, D., additional, Califano, C., additional, Falini, B., additional, Ciccone, G., additional, and Vitolo, U., additional

Published
2022
Full Text
View/download PDF

6. P1098: OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN MAINTENANCE TREATMENT WITH ANTICD20 MONOCLONAL ANTIBODIES IN SARS-COV2 ERA: RESULTS FROM A MULTICENTER, RETROSPECTIVE- PROSPECTIVE ITALIAN STUDY.

Author

Castellino, A., primary, Castellino, C., additional, Boccomini, C., additional, Clerico, M., additional, Nicoli, P., additional, Vanazzi, A., additional, Fanelli, F., additional, Perrone, T., additional, Marchesi, F., additional, Cocito, F., additional, Merli, M., additional, Bigliardi, S., additional, Mecacci, B., additional, Bozzoli, V., additional, Margiotta-Casaluci, G., additional, Meli, E., additional, Anastasia, A., additional, Farina, L., additional, Annibali, O., additional, Gottardi, D., additional, Zanni, M., additional, Conconi, A., additional, Ciochetto, C., additional, Cenfra, N., additional, Rotondo, F., additional, Ratotti, S., additional, Cuneo, A., additional, Selleri, C., additional, Galimberti, S., additional, and Massaia, M., additional

Published
2022
Full Text
View/download PDF

7. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study

Author

Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, Federico, M, Luminari, Stefano, Manni, Martina, Galimberti, Sara, Versari, Annibale, Tucci, Alessandra, Boccomini, Carola, Farina, Lucia, Olivieri, Jacopo, Marcheselli, Luigi, Guerra, Luca, Ferrero, Simone, Arcaini, Luca, Cavallo, Federica, Kovalchuk, Sofya, Skrypets, Tetiana, Del Giudice, Ilaria, Chauvie, Stephane, Patti, Caterina, Stelitano, Caterina, Ricci, Francesca, Pinto, Antonello, Margiotta Casaluci, Gloria, Zilioli, Vittorio R, Merli, Anna, Ladetto, Marco, Bolis, Silvia, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Anastasia, Antonella, Dondi, Alessandra, Mannina, Donato, Federico, Massimo, Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, Federico, M, Luminari, Stefano, Manni, Martina, Galimberti, Sara, Versari, Annibale, Tucci, Alessandra, Boccomini, Carola, Farina, Lucia, Olivieri, Jacopo, Marcheselli, Luigi, Guerra, Luca, Ferrero, Simone, Arcaini, Luca, Cavallo, Federica, Kovalchuk, Sofya, Skrypets, Tetiana, Del Giudice, Ilaria, Chauvie, Stephane, Patti, Caterina, Stelitano, Caterina, Ricci, Francesca, Pinto, Antonello, Margiotta Casaluci, Gloria, Zilioli, Vittorio R, Merli, Anna, Ladetto, Marco, Bolis, Silvia, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Anastasia, Antonella, Dondi, Alessandra, Mannina, Donato, and Federico, Massimo

Abstract

PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy. METHODS We randomly assigned treatment-naive, advanced-stage, high-tumor burden follicular lymphoma patients to receive standard RM or a response-adapted postinduction approach on the basis of metabolic response and molecular assessment of minimal residual disease (MRD). The experimental arm used three types of postinduction therapies: for complete metabolic response (CMR) and MRD-negative patients, observation; for CMR and MRD-positive (end of induction or follow-up) patients, four doses of rituximab (one per week, maximum three courses) until MRD-negative; and for non-CMR patients, one dose of ibritumomab tiuxetan followed by standard RM. The study was designed as noninferiority trial with progression-free survival (PFS) as the primary end point. RESULTS Overall, 807 patients were randomly assigned. After a median follow-up of 53 months (range, 1-92 months), patients in the standard arm had a significantly better PFS than those in the experimental arm (3-year PFS 86% v 72%; P < .001). The better PFS of the standard versus experimental arm was confirmed in all the study subgroups except non-CMR patients (n =65; P = .274). The 3-year overall survival was 98% (95% CI, 96 to 99) and 97% (95% CI, 95 to 99) in the reference and experimental arms, respectively (P = .238). CONCLUSION A metabolic and molecular response-adapted therapy as assessed in the FOLL12 study was associated with significantly inferior PFS compared with 2-year RM. The better efficacy of standard RM was confirmed in the subgroup analysis and particularly for patients achieving both CMR and MRDnegative.

Published
2022

10. COMBINED USE OF MINIMAL RESIDUAL DISEASE MONITORING AND FDG‐PET FOR OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA: RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIAL.

Author

Ferrero, S., Assanto, G. M., Durmo, R., Marcheselli, L., Mantoan, B., Pironti, M., Guerra, L., Boccomini, C., Puccini, B., Pulsoni, A., Pavone, V., Arcari, A., Califano, C., Castellino, C., Bari, A., Conconi, A., Dardanis, D., Chauvie, S., Gattei, V., and Del Giudice, I.

Subjects
FOLLICULAR lymphoma, POSITRON emission tomography, NON-Hodgkin's lymphoma
Abstract

B Discussion: b MRD analysis and PET scan are independent and complementary prognostic tools in FL: a MRD positivity in the two years after immuno-chemotherapy is predictive of POD24 and dismal PFS independently from the EoI PET result. This means that patients scoring PET- at EoI but showing a persistent or reappearing MRD+ signal during the following 24 months had a dismal PFS, superimposable to that of PET+ patients (Figure 1C). B Introduction: b In follicular lymphoma (FL), FDG-PET is routinely employed to evaluate response at the end of induction (EoI), while minimal residual disease (MRD) analysis is highly reliable in predicting relapse over the entire disease history. [Extracted from the article]

Published
2023
Full Text
View/download PDF

11. PO-1080 Low-dose radiotherapy (4 Gy) in the treatment of marginal zone B- cell lymphomas

Author

Cerrato, M., primary, Orlandi, E., additional, Vella, A., additional, Bartoncini, S., additional, Iorio, G.C., additional, Bongiovanni, D., additional, Capriotti, F., additional, Boccomini, C., additional, Vassallo, F., additional, Cavallin, C., additional, De Luca, V., additional, Giglioli, F.R., additional, Ricardi, U., additional, and Levis, M., additional

Published
2021
Full Text
View/download PDF

12. RESPONSE ADAPTED POST INDUCTION THERAPY IN FOLLICULAR LYMPHOMA: UPDATED RESULTS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Luminari, S., primary, Galimberti, S., additional, Versari, A., additional, Tucci, A., additional, Boccomini, C., additional, Farina, L., additional, Zaja, F., additional, Marcheselli, L., additional, Ferrero, S., additional, Arcaini, L., additional, Pulsoni, A., additional, Musuraca, G., additional, Califano, C., additional, Merli, M., additional, Bari, A., additional, Conconi, A., additional, Giudice, I. del, additional, Re, F., additional, Stefani, P. M., additional, Usai, S. V., additional, Perrone, T., additional, Gini, G., additional, Falini, B., additional, Gattei, V., additional, Manni, M., additional, Ladetto, M., additional, Mannina, D., additional, and Federico, M., additional

Published
2021
Full Text
View/download PDF

13. UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA

Author

Pulsoni, A., primary, Tosti, M. E., additional, Ferrero, S., additional, Luminari, S., additional, Dondi, A., additional, Liberati, A. M., additional, Cenfra, N., additional, Renzi, D., additional, Zanni, M., additional, Boccomini, C., additional, Ferreri, A. J., additional, Rattotti, S., additional, Zilioli, V. R., additional, Bernuzzi, P., additional, Bolis, S., additional, Musuraca, G., additional, Nassi, L., additional, Perrone, T., additional, Stelitano, C., additional, Anastasia, A., additional, Corradini, P., additional, Partesotti, G., additional, Re, F., additional, Cencini, E., additional, Mannarella, C., additional, Mannina, D., additional, Molinari, A. L., additional, Tani, M., additional, Annechini, G., additional, Assanto, G. M., additional, Grapulin, L., additional, Guarini, A., additional, Cavalli, M., additional, De Novi, L. A., additional, Ciabatti, E., additional, Mantoan, B., additional, Della Starza, I., additional, Arcaini, L., additional, Ricardi, U., additional, Gattei, V., additional, Galimberti, S., additional, Ladetto, M., additional, Foà, R., additional, and Del Giudice, I., additional

Published
2021
Full Text
View/download PDF

14. SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK

Author

Novak, U., primary, Fehr, M., additional, Schär, S., additional, Dreyling, M., additional, Scheubeck, G., additional, Ramadan, S., additional, Zucca, E., additional, Zander, T., additional, Hess, G., additional, Mey, U., additional, Ferrero, S., additional, Mach, N., additional, Boccomini, C., additional, Böttcher, S., additional, Voegeli, M., additional, Cairoli, A., additional, Menter, T., additional, Dirnhofer, S., additional, Gadient, S., additional, Eckhardt, K., additional, Driessen, C., additional, and Renner, C., additional

Published
2021
Full Text
View/download PDF

16. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi

Author

Luminari, S., Biasoli, I., Arcaini, L., Versari, A., Rusconi, C., Merli, F., Spina, M., Ferreri, A. J. M., Zinzani, P. L., Gallamini, A., Mastronardi, S., Boccomini, C., Gaidano, G., DʼArco, A. M., Di Raimondo, F., Carella, A. M., Santoro, A., Musto, P., and Federico, M.

Published
2013
Full Text
View/download PDF

18. IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA

Author

Batlevi, C.L., primary, Sha, F., additional, Alperovich, A., additional, Ni, A., additional, Smith, K., additional, Ying, Z., additional, Hamlin, P., additional, Horwitz, S.M., additional, Kumar, A., additional, Matasar, M., additional, Moskowitz, A.J., additional, Moskowitz, C.H., additional, Noy, A., additional, Palomba, M.L., additional, Portlock, C., additional, Straus, D., additional, Boccomini, C., additional, Tucci, A., additional, Zelenetz, A.D., additional, Seshan, V.E., additional, Luminari, S., additional, Marcheselli, L., additional, Federico, M., additional, and Younes, A., additional

Published
2019
Full Text
View/download PDF

19. RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI.

Author

Federico, M., primary, Mannina, D., additional, Versari, A., additional, Ferrero, S., additional, Marcheselli, L., additional, Boccomini, C., additional, Dondi, A., additional, Tucci, A., additional, Guerra, L., additional, Galimberti, S., additional, Cavallo, F., additional, Olivieri, J., additional, Corradini, P., additional, Arcaini, L., additional, Chauvie, S., additional, Del Giudice, I., additional, Rusconi, C., additional, Pinto, A., additional, Molinari, A., additional, Pulsoni, A., additional, Merli, M., additional, Kovalchuk, S., additional, Nassi, L., additional, Bolis, S., additional, Gattei, V., additional, Manni, M., additional, Pileri, S., additional, Brugiatelli, M., additional, and Luminari, S., additional

Published
2019
Full Text
View/download PDF

20. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

Author

Ladetto, M., Lobetti-Bodoni, C., Mantoan, B., Ceccarelli, M., Boccomini, C., Genuardi, E., Chiappella, A., Baldini, L., Rossi, G., Pulsoni, A., Di Raimondo, F., Rigacci, L., Pinto, A., Galimberti, S., Bari, A., Rota-Scalabrini, D., Ferrari, A., Zaja, F., Gallamini, A., Specchia, G., Musto, P., Rossi, F. G., Gamba, E., Evangelista, A., Vitolo, U., Fondazione Italiana Linfomi: Chiara Lobetti-Bodoni, Barbara, Mantoan, Elisa, Genuardi, Mario, Boccadoro, Marco, Ladetto, Giovannino, Ciccone, Andrea, Evangelista, Manuela, Ceccarelli, Carola, Boccomini, Annalisa, Chiappella, Barbara, Botto, Lorella, Orsucci, Umberto, Vitolo, Maria, Goldaniga, Francesca Gaia Rossi, Luca, Baldini, Chiara, Bottelli, Alessandra, Tucci, Giuseppe, Rossi, Alessandro, Pulsoni, Federico De Angelis, Eleonora, Russo, Maurizio, Martelli, Robin, Foà, Francesco Di Raimondo, Annalisa, Chiarenza, Luigi, Rigacci, Benedetta, Puccini, Alberto, Bosi, Antonello, Pinto, Mario, Petrini, Sara, Galimberti, Alessia, Bari, Stefano, Sacchi, Massimo, Federico, Delia, Rota-Scalabrini, Massimo, Aglietta, Angela, Ferrari, Isabel Alvarez De Celis, Francesco, Merli, Francesco, Zaja, Renato, Fanin, Claudia, Castellino, Andrea, Gallamini, Guido, Parvis, Giuseppe, Saglio, Tommasina, Perrone, Giorgina, Specchia, Pellegrino, Musto, Enrica, Gamba, Paolo, Corradini, Enrico Maria Pogliani, Anna Marina Liberati, Giuseppe, Leone, Caterina, Patti, Giuseppe, Fioritoni, Chiara, Rusconi, Enrica, Morra, Anna, Tonso, Giuseppina, Cabras, Emanuele, Angelucci, Andrea, Rossi, Alessandro, Rambaldi, Sergio, Cortelazzo, Sergio, Morandi, Lanza, Francesco, Giovanni, Pizzolo, Sergio, Amadori, Pier Luigi Zinzani, Caterina, Stelitano, Francesco, Nobile, Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U, Fondazione Italiana Linfomi, [Zinzani PL], Ladetto, M, Lobetti Bodoni, C, Mantoan, B, Ceccarelli, M, Boccomini, C, Genuardi, E, Chiappella, A, Baldini, L, Rossi, G, Pulsoni, A, Di Raimondo, F, Rigacci, L, Pinto, A, Galimberti, S, Bari, A, Rota Scalabrini, D, Ferrari, A, Zaja, Francesco, Gallamini, A, Specchia, G, Musto, P, Rossi, Fg, Gamba, E, Evangelista, A, and Vitolo, U.

Subjects
Aged, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Consolidation Chemotherapy, Disease-Free Survival, Female, Humans, Lymphoma, Follicular, Male, Middle Aged, Neoplasm, Residual, Oncogene Proteins, Fusion, Prognosis, Rituximab, Pathology, Lymphoma, Follicular lymphoma, Gastroenterology, Biochemistry, hemic and lymphatic diseases, Monoclonal, minimal resdual disease, bone marrow, follicular lymphomas, Oncogene Proteins, Hematology, Hazard ratio, medicine.anatomical_structure, Residual, Immunology, Cell Biology, medicine.drug, Murine-Derived, medicine.medical_specialty, Antibodies, NO, follicular lymphoma, Chemoimmunotherapy, Internal medicine, medicine, Fusion, business.industry, Follicular, medicine.disease, Minimal residual disease, Neoplasm, Bone marrow, business
Abstract

We assessed the prognostic value of minimal residual disease (MRD) within the ML17638 phase 3 trial from the Fondazione Italiana Linfomi, investigating the role of rituximab maintenance in elderly follicular lymphoma (FL) patients after a brief first-line chemoimmunotherapy. MRD for the bcl-2/IgH translocation was determined on bone marrow cells in a centralized laboratory belonging to the Euro-MRD consortium, using qualitative and quantitative polymerase chain reactions (PCRs). Of 234 enrolled patients, 227 (97%) were screened at diagnosis. A molecular marker (MM) was found in 51%. Patients with an MM were monitored at 8 subsequent times. Of the 675 expected follow-up samples, 83% were analyzed. Conversion to PCR negativity predicted better progression-free survival (PFS) at all post-treatment times (eg, end of therapy: 3-year PFS, 72% vs 39%; P < .007). MRD was predictive in both maintenance (83% vs 60%; P < .007) and observation (71% vs 50%; P < .001) groups. PCR positivity at the end of induction was an independent adverse predictor (hazard ratio, 3.1; 95% confidence interval, 1.36-7.07). MRD is a powerful independent outcome predictor in FL patients who receive rituximab-intensive programs, suggesting a need to investigate its value for decision-making. This trial was registered at www.clinicaltrial.gov as #NCT01144364.

Published
2013

21. CNS RELAPSE OF DIFFUSE LARGE B‐CELL LYMPHOMA AND ROLE OF UPFRONT PROPHYLAXIS: A 10‐YEAR SINGLE CENTER EXPERIENCE.

Author

Savelli, C. Benevolo, Novo, M., Fasano, F., Evangelista, A., Cavallo, F., Boccomini, C., Orsucci, L., Clerico, M., Peri, V., Bruno, B., Botto, B., and Freilone, R.

Subjects
DIFFUSE large B-cell lymphomas, PREVENTIVE medicine
Abstract

In univariate analysis CNS relapse risk was significantly influenced by ECOG PS and elevated LDH levels, while the use of prophylaxis was not shown to impact the risk of CNS recurrence. 95/397 pts received CNS prophylaxis (24%): 59 by intrathecal (IT) route only (15%) ( I n i 26 CNS-IPI 2-3; I n i 29 CNS-IPI 4-6), 25 by iv MTX only (6%) ( I n i 17 HD-MTX >=3 g/mq; n 6 CNS-IPI 2-3; I n i 16 CNS-IPI 4-6), and 11 by combined route (3%) ( I n i 5 CNS-IPI 2-3, I n i 6 CNS-IPI 3-6). 12 pts experienced CNS relapse; 8/12 exclusively CNS and 4/12 along with systemic recurrence. B Introduction: b Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a rare event, occurring in about 5% of patients (pts) and correlating with a very dismal prognosis. [Extracted from the article]

Published
2023
Full Text
View/download PDF

22. The impact of spleen metabolic tumor volume on total metabolic tumor volume and prognosis in patients with follicular lymphoma enrolled in FOLL 12 trial.

Author

Guerra, L., Chauvie, S., Marcheselli, L., Bergesio, F., Durmo, R., Peano, S., Franceschetto, A., Fallanca, F., Pinto, A., Ghiggi, C., Pulsoni, A., Merli, M., Farina, L., Tani, M., Boccomini, C., Musuraca, G., Falini, B., Ballerini, F., Stefani, P., and Bolis, S. A. M.

Subjects
FOLLICULAR lymphoma, SPLEEN, PROGRESSION-free survival, PROGNOSIS
Abstract

In the whole population of 690 patients, the tMTV threshold to categorized low and high tumor burden was 224 and 194 ml with and without sMTV, respectively. During the segmentation procedure, it has been observed that frequently spleen MTV (sMTV) heavily influenced the tMTV value, particularly in case of diffuse spleen uptake included in tMTV calculation. [Extracted from the article]

Published
2023
Full Text
View/download PDF

23. LONG TERM RESULTS OF THE FOLL05 RANDOMIZED STUDY COMPARING R-CVP WITH R-CHOP AND R-FM AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. A FIL STUDY

Author

Luminari, S., primary, Tarantino, V., additional, Anastasia, A., additional, Boccomini, C., additional, Chiarenza, A., additional, Rigacci, L., additional, Angelucci, E., additional, Ferrari, A., additional, Pulsoni, A., additional, Rattotti, S., additional, Angrilli, F., additional, Gaidano, G., additional, Stelitano, C., additional, Bertoldero, G., additional, Cascavilla, N., additional, Salvi, F., additional, Ferreri, A.J., additional, Vallisa, D., additional, Balzarotti, M., additional, Cox, M.C., additional, Freilone, R., additional, Marcheselli, L., additional, Dondi, A., additional, Manni, M., additional, and Federico, M., additional

Published
2017
Full Text
View/download PDF

24. A pooled data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL): Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in non-Hodgkin lymphoma (NHL)

Author

Santi, R.M., primary, Ceccarelli, M., additional, Monagheddu, C., additional, Evangelista, A., additional, Bernocco, E., additional, Monaco, F., additional, Federico, M., additional, Vitolo, U., additional, Cortellazzo, S., additional, Cabras, M.G., additional, Spina, M., additional, Baldini, L., additional, Boccomini, C., additional, Chiappella, A., additional, Bari, A., additional, Luminari, S., additional, Visco, C., additional, Contino, L., additional, Ciccone, G., additional, and Ladetto, M., additional

Published
2016
Full Text
View/download PDF

25. PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL)

Author

Santi, R.M., primary, Ceccarelli, M., additional, Catania, G., additional, Monagheddu, C., additional, Evangelista, A., additional, Bernocco, E., additional, Monaco, F., additional, Federico, M., additional, Vitolo, U., additional, Cortelazzo, S., additional, Cabras, M.G., additional, Spina, M., additional, Baldini, L., additional, Boccomini, C., additional, Chiappella, A., additional, Bari, A., additional, Luminari, S., additional, Calabrese, M., additional, Levis, A., additional, Visco, C., additional, Contino, L., additional, Ciccone, G., additional, and Ladetto, M., additional

Published
2016
Full Text
View/download PDF

26. Prognostic value of the end of induction PET in patients with follicular lymphoma: results from the analysis of FOLL 12 trial.

Author

Guerra, L., Bergesio, F., Fallanca, F., Chauvie, S., Marcheselli, L., Durmo, R., Peano, S., Franceschetto, A., Pinto, A., Tani, M., Merli, M., Boccomini, C., Musuraca, G., Pulsoni, A., Falini, B., Ghiggi, C., Farina, L., Ballerini, F., Stefani, P., and Bolis, S. A. M.

Subjects
FOLLICULAR lymphoma, PROGNOSIS, POSITRON emission tomography
Abstract

B Aim: b To assess the prognostic value of the PET metabolic response using the Deauville Score at the end of induction (EoI) therapy. In the whole population, the 5 yrs PFS (95% CI) in DS1-2, DS 3 ad DS4-5 was 74% (69-78), 55% (44-65; HR1.90 (1.36-2.66) I p i < 0.001) and 37%(26-48; HR 4.01 (2.90-5.54) I p i < 0.001); DS3 patients had an intermediate 5 yrs PFS rates between those of DS1-2 and DS4-5 patients. B Conclusion: b In FOLL12 trial, EoI-PET according DS criteria was a reliable tool to stratify PFS and OS in advanced follicular lymphoma patients treated with immunochemotherapy; in addition, these data showed DS3 patients as a new category with an intermediate prognosis in terms of PFS. [Extracted from the article]

Published
2023
Full Text
View/download PDF

27. PROGNOSTIC VALUE OF CEREBROSPINAL FLUID FLOW CYTOMETRY ANALYSIS IN AGGRESSIVE NHL PATIENTS AT HIGH RISK FOR LEPTOMENINGEAL DISEASE: FCM plus MAY PREDICT AN HIGH RISK OF CNS RELAPSE

Author

Benevolo, G., Pioltelli, P., Michele Spina, Boccomini, C., Stacchini, A., Evangelista, A., Godio, L., Mannelli, F., Franceschetti, S., Cantonetti, M., Di Rocco, A., Depaoli, L., Pavone, V., Di Renzo, N., Ferreri, A., Arras, M., Pogliani, E., and Vitolo, U.

Subjects
Settore MED/06 - Oncologia Medica, Settore MED/15 - Malattie del Sangue
Published
2010

29. Short term chemoimmunotherapy with rituximab (R)-FND +/-R maintenance as first line treatment in elderly patients with advanced follicular lymphoma: a prospective randomized trial by intergruppo italiano linfomi

Author

Boccomini, C, Ladetto, M, Gamba, E, Alvarez, I, Baldini, L, Ceccarelli, M, Chiapella, A, Corradini, P, DE RENZO, A, DI RAIMONDO, Francesco, Evangelista, A, Gallamini, A, Guarini, A, Hoaus, S, Liberati, A. M., Mantoan, B, Orsucci, L, Parvis, G, Petrini, M, Pinto, A, Pogliani, E, Pozzi, S, Pulsoni, A, Rigacci, L, Russo, E, Tarella, C, Tucci, A, AND VITOLO U, ZAIA F., and ON THE BEHALF OF INTERGRUPPO ITALIANO LINFOMI III

Published
2009

30. BRIEF CHEMOIMMUNOTHERAPY RITUXIMAB (R)-FND /- R MAINTENANCE IS EFFECTIVE AND SAFE IN NEWLY DIAGNOSED FOLLICULAR LYMPHOMA ELDERLY PATIENTS: AN INTERGRUPPO ITALIANO LINFOMI (IIL) RANDOMIZED TRIAL

Author

Vitolo, U., Ladetto, M., Boccomini, C., Gamba, E., Alvarez, I., Baldini, L., Chiappella, A., Corradini, P., DE RENZO, A., DI RAIMONDO, Francesco, Evangelista, A., Gallamini, A., Guarini, A., Mantoan, B., Martelli, M., Orsucci, L., Parvis, G., Petrini, M., Pinto, A., Pozzi, S., Pulsoni, A., Rigacci, L., Russo, E., Tarella, C., Tucci, A., Zaja, F., Gallo, E., and MAINTENANCE IS EFFECTIVE AND SAFE IN NEWLY DIAGNOSED FOLLICULAR LYMPHOMA ELDERLY PATIENTS AN INTERGRUPPO ITALIANO LINFOMI IIL RANDOMIZED TRIAL, BRIEF CHEMOIMMUNOTHERAPY RITUXIMAB R. FND R.

Published
2009

31. GALLOELDERLY PATIENTS WITH UNTREATED ADVANCED STAGE FOLLICULAR LYMPHOMA (FL) TREATED WITH BRIEF CHEMOIMMUNOTHERAPY RITUXIMAB (R)FND+/-RITUXIMAB MAINTENANCE: PRELIMINARY ANALYSIS OF A PROSPECTIVE RANDOMIZED STUDY 333

Author

Vitolo, U., Ladetto, M., Boccomini, C., Gamba, E., Baldini, L., Ceccarelli, M., Chiappella, A., DE RENZO, A., DI RAIMONDO, Francesco, Gallamini, A., Mantoan, B., Martelli, M., Alvarez, I., Parvis, G., Petrini, M., Pinto, A., Pozzi, S., Pulsoni, A., Rigacci, L., Tucci, A., Zaja, F., and Gallo, E.

Published
2008

32. BRIEF CHEMOIMMUNOTHERAPY WITH RITUXIMAB (R)-FND /- R MAINTENANCE AS FIRST LINE TREATMENT IN ADVANCED FOLLICULAR LYMPHOMA (FL) IN ELDERLY: PRELIMINARY ANALYSIS OF A PROSPECTIVE RANDOMIZED TRIAL

Author

Vitolo, U., Ladetto, M., Boccomini, C., Gamba, E., Alvarez, I., Baldini, L., Ceccarelli, M., ANNALISA CHIAPPELLA, Corradini, P., Renzo, A., Di Raimondo, F., Gallamini, A., Guarini, A., Mantoan, B., Marrelli, M., Naso, V., Parvis, G., Petrini, M., Pinto, P., Pozzi, S., Pulsoni, A., Rigacci, L., Tarella, C., Tucci, A., Zaja, F., and Gallo, E.

Published
2008

34. Concurrrent rituximab with dose-dense MegaCEOP chemotherapy and high dose mitoxantrone, Ara-C and desamethasone (MAD) followed by BEAM and autologous stem cell transplantation (ASCT) is feasible and effective in high risk diffuse large B cell lymphoma (B-DLCL): a multicenter pilot study. (Abstract)

Author

Vitolo, U, Liberati, Anna Marina, Cabras, M. G., Rossi, G, Levis, A, Pavone, E, Angelucci, E, Boccomini, C, Bonella, L, Botto, B, Chiappella, A, DI VITO, F, Palumbo, Isabella, Pogliani, E, ROTA SCALABRINI, D, Salvi, F, Tonso, A, Tucci, A, and Gallo, E.

Subjects
rituximab, high risk, diffuse large B-cell lymphoma
Published
2004

40. The GITMO experience with high-dose chemotherapy and autografting in advanced follicle centre lymphoma (FCL): A multicenter trial showing good feasibility and frequent achievement of clinical and molecular remissions

Author

Ladetto, M., Corradini, P., Sametti, S., Vallet, S., Astolfi, M., Ricca, I., Benedetti, F., Boccomini, C., Brugiatelli, M., Chisesi, T., Coser, P., De Crescenzo, A., Di Renzo, N., Fioritoni, G., Gallamini, A., Levis, A., Majolino, I., Martelli, Maurizio, Morandi, S., Musso, M., Perrotti, A., Santini, G., Vitolo, U., Vivaldi, P., Zambello, R., Pizzolo, G., Gallo, E., Pileri, A., and Tarella, C.

Published
2001

41. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi

Author

Federico M, Vitolo U, Pl, Zinzani, Chisesi T, Clò V, Bellesi G, Magagnoli M, Liberati M, Boccomini C, Niscola P, Pavone V, Cuneo A, Santini G, Brugiatelli M, Luca Baldini, Rigacci L, and Resegotti L

Subjects
Adult, Male, Risk, NON-HODGKINS-LYMPHOMA, BONE-MARROW TRANSPLANTATION, LOW-GRADE LYMPHOMA, SINGLE-AGENT CHEMOTHERAPY, HIGH-DOSE THERAPY, B-CELL LYMPHOMA, COMBINATION CHEMOTHERAPY, MULTIVARIATE-ANALYSIS, MALIGNANT-LYMPHOMAS, NATURAL-HISTORY, Fever, Sweating, Blood Sedimentation, Weight Loss, Biomarkers, Tumor, Humans, Lymphoma, Follicular, Serum Albumin, Aged, Neoplasm Staging, Retrospective Studies, L-Lactate Dehydrogenase, Middle Aged, Prognosis, Combined Modality Therapy, Neoplasm Proteins, Survival Rate, Italy, Multivariate Analysis, Female
Abstract

Patients (n-987) with a histologically confirmed diagnosis of follicular lymphoma were studied with the aim of developing a prognostic model specifically devised for this type of lymphoma. We collected information on age, sex, Ann Arbor stage, number of extranodal disease sites, bone marrow (BM) involvement, bulky disease, B symptom criteria (fever, night sweats, and weight loss), performance status (PS), serum lactate dehydrogenase (LDH) level, serum albumin level, hemoglobin level, and erythrocyte sedimentation rate (ESR). In the training sample of 429 patients with complete data, multivariate analysis showed that age, sex, number of extranodal sites, B symptoms, serum LDH level, and ESR were factors predictive for overall survival. Using these 6 variables, a prognostic model was devised to identify 3 groups at different risk. The 5- and 10-year survival rate was 90% and 65% for patients at low risk, respectively; 75% and 54% for patients at intermediate risk; and 38% and 11% for those at high risk (log-rank test, 86.62; P. 0001). The model was also predictive (P =.0001) in the validation sample of 265 patients with complete data only for the 6 variables used in the development of the model and even in the group of 210 patients from the validation sample uniformly treated with doxorubicin-containing regimens (P =.0001). The prognostic model appears to be very useful in identifying patients with follicular lymphoma at low, intermediate, or high risk.

Published
2000

42. 918P - A pooled data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL): Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in non-Hodgkin lymphoma (NHL)

Author

Santi, R.M., Ceccarelli, M., Monagheddu, C., Evangelista, A., Bernocco, E., Monaco, F., Federico, M., Vitolo, U., Cortellazzo, S., Cabras, M.G., Spina, M., Baldini, L., Boccomini, C., Chiappella, A., Bari, A., Luminari, S., Visco, C., Contino, L., Ciccone, G., and Ladetto, M.

Published
2016
Full Text
View/download PDF

44. P002 Clinical and epidemiological considerations on myelodysplastic syndromes (MDS). The experience of the Piedmont MDS Register

Author

Gioia, D., primary, Cilloni, D., additional, Salvi, F., additional, Audisio, E., additional, Boccomini, C., additional, Bonferroni, M., additional, Cametti, G., additional, Ciravegna, G., additional, Darbesio, A., additional, Dellacasa, C., additional, Ferrero, D., additional, Freilone, R., additional, Gatto, S., additional, Lunghi, M., additional, Gallamini, A., additional, Gaidano, G., additional, Girotto, M., additional, Marmont, F., additional, Marinone, C., additional, Messa, E., additional, Perticone, S., additional, Pollio, B., additional, Tonso, A., additional, Saglio, G., additional, and Levis, A., additional

Published
2007
Full Text
View/download PDF

45. P104 Prognostic role of transfusion requirement in myelodysplastic syndromes

Author

Salvi, F., primary, Gioia, D., additional, Cilloni, D., additional, Audisio, E., additional, Boccomini, C., additional, Bonferroni, M., additional, Cametti, G., additional, Ciravegna, G., additional, Darbesio, A., additional, Dellacasa, C., additional, Ferrero, D., additional, Freilone, R., additional, Lunghi, M., additional, Gallamini, A., additional, Gaidano, G., additional, Girotto, M., additional, Marmont, F., additional, Tonso, A., additional, Saglio, G., additional, and Levis, A., additional

Published
2007
Full Text
View/download PDF

47. Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL)

Author

Santi, R. M., Ceccarelli, M., Catania, G., Monagheddu, C., Evangelista, A., Bernocco, E., Monaco, F., Federico, M., Vitolo, U., Cortelazzo, S., Cabras, M. G., Spina, M., Baldini, L., Boccomini, C., Chiappella, A., ALESSIA BARI, Luminari, S., Calabrese, M., Levis, A., Visco, C., Contino, L., Ciccone, G., and Ladetto, M.

50. POOLED DATA ANALYSIS OF TWELVE CLINICAL TRIALS OF FONDAZIONE ITALIANA LINFOMI (FIL): KHORANA SCORE AND HISTOTYPE PREDICT THE INCIDENCE OF EARLY VENOUS THROMBOEMBOLISM (VTE) IN NON HODGKIN LYMPHOMA

Author

Santi, R. M., Ceccarelli, M., Catania, G., Monagheddu, C., Evangelista, A., Bernocco, E., Monaco, F., Federico, M., Vitolo, U., Cortellazzo, S., Cabras, M. G., Spina, M., Baldini, L., Boccomini, C., Chiappella, A., Bari, A., stefano luminari, Visco, C., Calabrese, M., Contino, L., Ciccone, G., and Ladetto, M.

Catalog

Books, media, physical & digital resources
See catalog results